Oxford, UK – June 30, 2025 – U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, is thrilled to announce its first appearance at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting 2025, held this year in Paris, France.

Recognised as the premier global event in reproductive medicine, ESHRE 2025 brings together thousands of clinicians, embryologists, scientists, and industry leaders at the cutting edge of fertility care. U‑Ploid’s participation marks a significant milestone for the company as it steps onto the international stage to share its vision for a new generation of fertility therapeutics.

U‑Ploid will be hosted at Stand D068 by Caring IVF, where it will introduce its lead programme targeting age related oocyte quality decline, a leading cause of failed conception in women over 35. The company’s approach aims to improve egg quality, unlocking new possibilities for women over 35 who have long been underserved by traditional fertility treatments.

“We’re proud to be attending ESHRE for the first time and joining the global dialogue on the future of reproductive care,” said Dr Alexandre Webster, Co-founder & CSO of U‑Ploid. “As the field looks to improve outcomes for an increasingly age-diverse patient population, we believe therapeutics targeting egg quality represent an important and timely new direction.”

This debut comes on the heels of rapid momentum for the company, including its recent selection to the Merck Corporate Accelerator Programme and expanded partnerships across the fertility ecosystem.

‍About U-Ploid Biotechnologies

U-Ploid is a biotechnology company developing next-generation fertility therapeutics to address the global challenge of age-related infertility. Co-founded by Jordan Abdi, Chloe Charalambous, and Alexandre Webster, U-Ploid is pioneering innovative solutions to improve IVF outcomes and expand the window of reproductive opportunity. The company's technology is designed to increase the quality of older eggs, restoring their potential to support healthy pregnancies. U-Ploid is committed to improving access to fertility care and envisions a future where anyone who wants to start a family, can. For more information, go to u-ploid.com or follow us on LinkedIn.

Press and Investor Contact

press@u-ploid.com